Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models

Neurobiology of Disease

Volumn 73, Issue , 2015, Pages 388-398

  Träger, Ulrike ^a   Andre, Ralph ^a   Magnusson Lind, Anna ^a,b   Miller, James R C ^a   Connolly, Colúm ^c   Weiss, Andreas ^d,f   Grueninger, Stephan ^d   Silajdžić, Edina ^b   Smith, Donna L ^e   Leavitt, Blair R ^c   Bates, Gillian P ^e   Björkqvist, Maria ^b   Tabrizi, Sarah J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NOVARTIS PHARMA AG   (Switzerland)

^e GUY S HOSPITAL   (United Kingdom)

^f IRBM   (Italy)

Author keywords

Animal models of disease; Cytokines; Huntington's disease; Innate immune system; Myeloid cells; Neurodegeneration; Neuroinflammation

Indexed keywords

CD11B ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BRAIN SIZE; CELL ADHESION; CELL FUNCTION; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; GENE EXPRESSION PROFILING; HUNTINGTON CHOREA; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LIFESPAN; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PROTEIN BLOOD LEVEL; TISSUE DISTRIBUTION; ANIMAL; C57BL MOUSE; DISEASE MODEL; FEMALE; IMMUNOLOGY; INFLAMMATION; MALE;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; IMMUNITY, INNATE; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MYELOID CELLS;

EID: 84909609615     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.10.012     Document Type: Article

References (29)

1. Beck G., Habicht G.S. Immunity and the invertebrates. Sci. Am. 1996, 275(60-3):66.
2. Bjorkqvist M., et al. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:1713-1721.
3. Bjorkqvist M., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
4. Crook Z.R., Houseman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69:423-435.
5. Hockly E., et al. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull. 2003, 61:469-479.
6. Imhof B.A., Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat. Rev. Immunol. 2004, 4:432-444.
7. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000, 287:1837-1840.
8. Kuhn A., et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 2007, 16:1845-1861.
9. Kwan W., et al. Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J. Neurosci. 2012, 32:133-142.
10. Kwan W., et al. Mutant huntingtin impairs immune cell migration in Huntington disease. J. Clin. Invest. 2012, 122:4737-4747.
11. Labbadia J., et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J. Clin. Invest. 2011, 121:3306-3319.
12. Li J.Y., et al. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2005, 2:447-464.
13. Lin C.H., et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 2001, 10:137-144.
14. Mangiarini L., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
15. Moffitt H., et al. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS ONE 2009, 4:e8025.
16. Parker J.A., et al. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:13318-13323.
17. Sathasivam K., et al. Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum. Med. Genet. 2010, 19:65-78.
18. Sathasivam K., et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2366-2370.
19. Slow E.J., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2003, 12:1555-1567.
20. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
21. Träger U., et al. Immune dysfunction in human HD myeloid cells is caused by NFκB pathway dysregulation and is reversed by lowering HTT levels. Brain 2014, 137:819-833.
22. van der Burg J.M., et al. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009, 8:765-774.
23. Van Raamsdonk J.M., et al. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2005, 14:3823-3835.
24. Voisine C., et al. Identification of potential therapeutic drugs for Huntington's disease using Caenorhabditis elegans. PLoS ONE 2007, 2:e504.
25. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
26. Weiss A., et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J. Clin. Invest. 2012, 122:3731-3736.
27. Wild E., et al. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr. 2011, 3. (RRN1231).
28. Woodman B., et al. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 2007, 72:83-97.
29. Yang S.H., et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008, 453:921-924.